http://www.reportbuyer.com/rss.htmlLearn more about Oncology in the Pharma & Healthcare industry. Reports provide information on Current & Future Therapies for Cancer and Forecasting.en-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/protein_kinase_therapeutics_oncology.htmlThis report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target profiles, and assesses them in 57 different cancer indications. The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. b77094dcf923e642e4e4de5a74866a15Sat, 10 Oct 2009 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/asco_2009_significant_developments_context.htmlThe recent ASCO meeting was attended by around 30,000 cancer researchers and physicians and over 4,000 abstracts covering a wide range of clinical trial results and related topics were presented. How do you make sense of it all and, more importantly, what were the developments that were really important? This new FirstWord Dossier brings clarity and insight FirstWord's new analysis of the latest ASCO meeting highlights and presents selected information on the significant announcements from the conference in an easy-to-use digest. FirstWord's team of experienced medical journalists were on-hand to critically review and report the latest developments and thinking and this information, augmented by pre- and post-conference data released by developers, is the basis of this detailed 175-page research dossier. 116a6f0f82e48c0321c34d3ae72b49aaTue, 07 Jul 2009 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/analytical_tool_angiogenesis_oncology.html"Analytical Tool - Angiogenesis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in anti-angiogenic drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. 56be0129b642d75d78a0fc6f7308d3dfThu, 01 Jan 2009 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/analytical_tool_protein_kinase_inhibitors_oncology.html"Analytical Tool - Protein Kinase Inhibitors in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in the drug development of protein kinase inhibitors (PKIs) for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. c0f16cafa587deb78fca7f7c8669334bThu, 01 Jan 2009 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/analytical_tool_colorectal_cancer.htmlExecutive Summary "Analytical Tool - Colorectal Cancer"" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in colorectal cancer R&D and business development. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. 1e450788065f65797f635711c327bd0cThu, 01 Jan 2009 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/oncology_roadmap_1.htmlThis report entails comprehensive forecasts and detailed Budget Benchmarks. Cutting Edge Information's new report, "Oncology Roadmap," explores the fiercely competitive oncology market in a way that no other available forecast can match. Our experienced analysts have reviewed thousands of historical and forecasted data points to provide the most comprehensive oncology market outlook ever. 6ff4d94bed8a1ea12f31bfae0423f423Thu, 01 Jan 2009 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/u_s_radiotherapy_market.htmlThis research service provides the market information on the global radiotherapy and radiosurgery markets, with specific focus on the United States. . 6b1e27a301f0f873e0fb6fdb762f64c7Fri, 12 Dec 2008 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/stakeholder_opinions_bladder_cancer_new_drugs_needed_challenge_ineffective_20year_old_drugs.html The overall incidence of bladder cancer in the seven major markets is forecast to exceed 160,000 by the end of 2008. Treatment of bladder cancer employs mainly immunotherapy and chemotherapy. However, both these methods are ineffective in improving longterm survival. bcdaa5a595002385d66e22a53a741ff4Tue, 11 Nov 2008 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/oncology_market_leaders.htmlThe UK government have told kidney cancer patients that new drugs cannot be offered on the National Health Service. Roche's Avastin, Bayer's Nexavar, Pfizer's Sutent and Wyeth's Torisel were not cost-effective. The drugs -- known generically as bevacizumab, sorafenib, sunitinib and temsirolimus -- should therefore not be a treatment option for advanced and/or metastatic kidney cancer, NICE said. 8f13c505d3cf4f6adcd5d4984f4f1de8Fri, 10 Oct 2008 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/strategic_analysis_oncology_services_sub_saharan_africa.htmlResearch was carried out on the oncology healthcare industries in three countries, namely Kenya, Nigeria and Tanzania. A thorough PESTLE (political, economic, social, technology, legal and environmental) analysis was established for all the countries allowing for an accurate evaluation of the external factors impacting the oncology industries. Market sizes of the oncology sectors were calculated for 2006 and forecasts determined for the period 2006 to 2012. 9e042e96653ff54ec5cdcaf763122b10Tue, 09 Sep 2008 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/oncology_market_forecast_2013.htmlDisclaimer: Please note that the Report Price refers to up to 5 user license pdf format of the report. Give Your Team Access to the Most Comprehensive Oncology Forecast Ever Created. Cutting Edge Information's new report, Oncology Market Forecast to 2013, explores the fiercely competitive oncology market in a way that no other available forecast can match. 3ff50beaff39e567293bc9d842efcb17Tue, 01 Jul 2008 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/pipeline_insight_non_small_cell_lung_cancer.html Non-small cell lung cancer accounts for about 80% of all lung cancers. In 2008, the incidence of NSCLC is forecast to exceed 367,000 new cases in the seven major pharmaceutical markets. The high incidence of the disease and the large unmet need make NSCLC an attractive market for new drug development. 9b01ba8934e515f54bcc423f9856da67Thu, 17 Apr 2008 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/pipeline_insight_breast_cancer.html Incidence of breast cancer in the seven major markets will total 455,000 in 2008, while 115,000 women will die from the disease. Despite advances in treatment over the past decade, significant unmet needs remain. This level of demand and the large patient potential make breast cancer a relatively attractive indication for drug developers. e10dab96a009719ac7ca50fcb0cff5a1Thu, 17 Apr 2008 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/clinical_information_systems_europe_oncology.htmlThis research examines the clinical information systems-oncology markets in Europe in terms of the challenges faced by market participants, drivers and restraints in the industry, the competitive structure in the major markets, the revenue forecasts and growth rates and strategic recommendations. . 84f7a7fa9b39d0c4970f2e8751622971Fri, 04 Apr 2008 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/deployment_antibody_technologies_advancement_cancer_therapeutics.htmlThe discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody (mAb)-based technologies have rapidly developed into one of the major market segments of the pharmaceutical industry. By analyzing R&D pipelines and the platform technologies in use today, it is possible to better predict where the market will be in the next decade and to envisage which new innovative therapies will become market successes. 51e7fe594b3a2078e9c9e3a4f963ae7dFri, 04 Apr 2008 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/decoding_big_pharmas_r_d_strategy_oncology.htmlThis report, Decoding Big Pharma's R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. 9aa6d2c17be8f35393cb72f39e4408fdSun, 09 Sep 2007 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/drug_targets_breast_cancer.htmlIn Europe consolidation has been the order of the day throughout 2006, with many mid-sized companies being acquired - Bayer acquiring Schering AG, Schwarz bought by UCB to name a few. The implications of these and other mergers will be seen in the coming year in company strategy. On the regulatory front, Europe has been getting to grips with the additional requirements placed on the pharmaceutical companies as well as the regulatory agencies by the 2005 revisions of the EU pharmaceutical legislation coming into force. 0a682acce54f3ca3cd8fd3b1a330d516Sat, 07 Jan 2006 12:00:00 GBTherapeutic/Oncologyhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/oncology/oncology_brand_commercialization.html Oncology Brand Commercialization: Resource Allocation (PH68) Use this report's 28 commercial variables to build your own, customized data sets for cancer drug launches. By combining spending and staffing data from the report's 28 different brand types, you can build resource benchmarks to fit your own unique challenges. The report's data sets are divided into 10 chapters: Chapter 1: Drug Class - Explores resources for cytotoxics and innovative therapies Chapter 2: Market Entrance - Explores resources for first-to-market brands and follow-on/me-too brands Chapter 3: Indications - Explores resources for brands indicated to treat leukemia, breast cancer, lung cancer, prostate cancer and colorectal cancer Chapter 4: Peak Sales - Explores resources for brands with projected peak annual sales of more than $1 billion, $500 million to $999 million, and less than $500 million Chapter 5: Line of Treatment - Explores resources for first-line, second-line and third-line therapeutics Chapter 6: Clinical Profile - Explores resources for brands with favorable, average, and unfavorable clinical profiles Chapter 7: Industry Sector - Explores resources for brands commercially supported by major pharmaceutical companies and by biotechnology companies Chapter 8: Competitive Landscape - Explores resources for brands with strong, average and weak competitive positions Chapter 9: Promotional Infrastructure - Explores resources for brands with access to strong, average and weak internal resources Chapter 10: Drug Delivery - Explores resources for brands delivered orally and intravenously . 121774b3dea4bf8f342c388e61ceb781Sun, 01 May 2005 12:00:00 GBTherapeutic/Oncology